14. (New) A compound according to claim 13, which provides the X-ray powder diffraction pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 °2θ.

15. (New) A compound according to claim 13, which in a mineral oil dispersion provides an infra red spectrum substantially in accordance with Figure I.

16. (New) A compound according to claim 13, which provides an X-ray powder diffraction pattern substantially in accordance with Figure II.

17. (New) A compound according to claim 13, in isolated form.

B1 cont.

18. (New) A process for preparing a compound according to claim 13, comprising treating 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione with a source of hydrochloride counter-ion and an appropriate amount of water for formation of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate.

19. (New) The process according to claim 18, further comprising the step of recovering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate.

20. (New) A pharmaceutical composition comprising an effective, non-toxic amount of the compound according to claim 13 and a pharmaceutically acceptable carrier therefor.

21. (New) A pharmaceutical composition consisting essentially of an effective, non-toxic amount of the compound according to claim 13 and a pharmaceutically acceptable carrier therefor.

22. (New) A method for the treatment or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the compound according to claim 13 to a human or non-human mammal in need thereof.